---
title: "Biotech leader eyes spin-off amid massive sales surge"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274701201.md"
description: "Biotech stock Anaptysbio cleared a trendline entry near 50 on Monday. Shares are also in a base with a buy point of 52.47."
datetime: "2026-02-03T19:15:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274701201.md)
  - [en](https://longbridge.com/en/news/274701201.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274701201.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274701201.md) | [繁體中文](https://longbridge.com/zh-HK/news/274701201.md)


# Biotech leader eyes spin-off amid massive sales surge

Biotech stock Anaptysbio cleared a trendline entry near 50 on Monday. Shares are also in a base with a buy point of 52.47.

### Related Stocks

- [AnaptysBio, Inc. (ANAB.US)](https://longbridge.com/en/quote/ANAB.US.md)

## Related News & Research

- [What is HC Wainwright's Estimate for AnaptysBio Q1 Earnings?](https://longbridge.com/en/news/278095134.md)
- [Biotech startups are built on venture capital. Track funding rounds here.](https://longbridge.com/en/news/279063001.md)
- [1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade](https://longbridge.com/en/news/278573307.md)
- [BioNTech's founding couple Sahin, Tuereci to leave to set up new venture](https://longbridge.com/en/news/278538947.md)
- [Abivax spokesperson denies takeover rumors reported by French media](https://longbridge.com/en/news/278902708.md)